GLP-1 TV · Clinician · 7 videos
Dr. Amin Hedayat, MD
@DrAminHedayat on YouTube ↗Dr. Amin Hedayat, MD is a YouTube channel of clinicians explaining GLP-1 medications, with 173K subscribers and a verified badge. GLP-1 TV holds 7 of its videos, 2.1M views between them, the newest from Sep 2026. The speaker in most of them is Dr. Amin Hedayat, MD, as the videos introduce them.
- Medications covered
- Ozempic (7), Mounjaro (5), Foundayo (1)
- Topics that come up most
- Dose change, Weigh-in and results, How it works, The trials, Stopping and maintenance, Side effects
16:12I’m a Pathologist. Retatrutide is NOT Ozempic. It’s Biological Overdrive.Dr. Amin Hedayat, MDDetails8 key moments
Dr. Amin Hedayat, who describes himself as a triple board certified pathologist and assistant clinical professor, reviews what he says the published data show about retatrutide.
- 0:00 The "Power-Wash" Molecule
- 2:25 The FDA & Gray Market Warning
- 3:56 Why Dieting Fails: Hardware vs. Software
- 5:19 The Hypothalamus: Metabolism's Air Traffic Control
- 6:23 The "Triple-Lock" Master Key & Glucagon Paradox
- 8:02 Power-Washing the Liver (MASLD Recovery)
- 9:40 The Heart Price Tag: Tachycardia Risks
- 10:49 Muscle Wasting & Sarcopenia
- Side effects mentioned: nausea
- Who is speaking: Clinician, MD (Dr. Amin Hedayat)
39:58Ozempic & Mounjaro: Same Shot. Opposite Results.Dr. Amin Hedayat, MDDetails8 key moments
In this video, Dr. Amin Hedayat, who describes himself as a triple board certified physician and assistant clinical professor, argues that the same GLP-1 medication can help one person and harm another.
- 0:00 The Paradox: Same Drug, Opposite Outcomes
- 2:21 Weight Loss ≠ Metabolic Repair (Critical Concept)
- 4:50 How GLP-1s Actually Work (Beyond Appetite)
- 14:21 The 3-Dial Framework: Who Thrives vs Who Struggles
- 16:33 Thrive Phenotype A: High Appetite Drive + Insulin Resistance
- 18:12 Thrive Phenotype B: Inflammation-Driven Weight
- 19:02 Thrive Phenotype C: Cardiometabolic High Risk
- 20:17 Deterioration Phenotype 1: Low Reserve/Frailty Risk
- Doses mentioned: 2.4 mg
- Side effects mentioned: nausea, constipation, fatigue, hair loss, heartburn or reflux, bloating, muscle loss, low appetite, gallbladder and pancreatitis
- Who is speaking: Clinician, MD (Dr. Amin Hedayat)
25:10I'm a Pathologist. Do This When Ozempic & Mounjaro "Stop Working."Dr. Amin Hedayat, MDDetails
A clinician (MD) looks at what life on Ozempic is like. Also covers stopping and maintenance.
- Who is speaking: Clinician, MD (Dr. Amin Hedayat)
26:48I’m a Pathologist. The Ozempic & Mounjaro Cost You Can’t Feel Yet.Dr. Amin Hedayat, MDDetails
A clinician (MD) talks through Ozempic side effects. It has no captions we could read, so this is drawn from its title and description.
- Who is speaking: Clinician, MD (Dr. Amin Hedayat)
29:46The Biology of Trauma & Weight Gain: Ozempic & Mounjaro Can’t Fix This (Ep. 2)Dr. Amin Hedayat, MDDetails8 key moments
A clinician (MD) looks at what life on Ozempic is like. Side effects mentioned: fatigue. Also covers mood and mental health, stopping and maintenance and how it works.
- 0:00 The Overlooked Cause of Obesity
- 2:48 The Discovery of the ACE Study
- 7:03 The HPA Axis: Your Brain on Chronic Stress
- 10:30 Cortisol & The Visceral Fat Bunker
- 12:40 Why Dieting Feels Starving
- 14:08 Epigenetics: How Trauma Rewires Your DNA
- 18:37 Food as a Sedative (The Biology of Cravings)
- 20:57 The Armor Paradox: Why We Self-Sabotage
- Side effects mentioned: fatigue
- Who is speaking: Clinician, MD (Dr. Amin Hedayat)
20:42Foundayo: New "Ozempic in a Pill". Here's the Catch.Dr. Amin Hedayat, MDDetails8 key moments
Dr. Amin Hedayat, who describes himself as a physician, triple board-certified pathologist and assistant clinical professor of medicine, covers Foundayo (orforglipron), a daily pill from Eli Lilly that he says the FDA approved on April 1, 2026.
- 0:00 Is the New Ozempic Pill Dangerous?
- 3:08 How GLP-1 Weight Loss Drugs Actually Work
- 4:50 Why Old GLP-1s Required Injections
- 6:02 How the New Daily Weight Loss Pill Works
- 7:42 The Muscle Loss Trap: Why Your Scale is Lying
- 11:08 Ozempic Face & Muscle Wasting Explained
- 12:06 Strategy 1: The Protein Threshold (mTOR)
- 14:14 Strategy 2: Resistance Training & Mechanical Tension
- Weight loss mentioned: 40 lb
- Side effects mentioned: low appetite
- Who is speaking: Clinician, MD (Dr. Amin Hedayat)
12:49I'm a Dermatopathologist. Hair Loss on Ozempic and MounjaroDr. Amin Hedayat, MDDetails
A clinician (MD) talks through Ozempic side effects. Side effects mentioned: hair loss.
- Side effects mentioned: hair loss
- Who is speaking: Clinician, MD (Dr. Amin Hedayat)
Where semaglutide costs least today
The three cheapest partner programs for semaglutide, all in per month, checked weekly. Brand Ozempic and compounded versions are different products; each row says which it is.
What each Dr. Amin Hedayat, MD video covers
The opening line of our summary for each video, most-watched first.
- I’m a Pathologist. Retatrutide is NOT Ozempic. It’s Biological Overdrive.
Dr. Amin Hedayat, who describes himself as a triple board certified pathologist and assistant clinical professor, reviews what he says the published data show about retatrutide.
881K views · Mar 2026 - Ozempic & Mounjaro: Same Shot. Opposite Results.
In this video, Dr. Amin Hedayat, who describes himself as a triple board certified physician and assistant clinical professor, argues that the same GLP-1 medication can help one person and harm another.
591K views · Feb 2026 - Foundayo: New "Ozempic in a Pill". Here's the Catch.
Dr. Amin Hedayat, who describes himself as a physician, triple board-certified pathologist and assistant clinical professor of medicine, covers Foundayo (orforglipron), a daily pill from Eli Lilly that he says the FDA approved on April 1, 2026.
18.5K views · Jun 2026
Watched them? See what it costs.
Every GLP-1 program we track, ranked by what actually leaves your account.